Detalhe da pesquisa
1.
Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study.
Ann Neurol
; 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38529711
2.
Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies.
Ann Rheum Dis
; 83(2): 177-183, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37932010
3.
Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study.
J Neurol Neurosurg Psychiatry
; 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38744458
4.
Trajectories of self-reported fatigue following initiation of multiple sclerosis disease-modifying therapy.
J Neurol Neurosurg Psychiatry
; 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38744460
5.
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy.
J Neurol Neurosurg Psychiatry
; 95(2): 134-141, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37558400
6.
Combining Mendelian randomization with the sibling comparison design.
Stat Med
; 43(4): 731-755, 2024 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38073579
7.
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
Ann Rheum Dis
; 82(7): 911-919, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36868796
8.
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
Ann Rheum Dis
; 82(2): 189-197, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36150749
9.
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme.
Ann Rheum Dis
; 82(5): 601-610, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36787994
10.
Glucocorticoid exposure and the risk of serious infections in rheumatoid arthritis: a marginal structural model application.
Rheumatology (Oxford)
; 62(10): 3391-3399, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36821426
11.
Genome-wide investigation of persistence to treatment with methotrexate in early rheumatoid arthritis.
Rheumatology (Oxford)
; 2023 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37326842
12.
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study.
Mult Scler
; 29(6): 731-740, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37073483
13.
The Swedish medical birth register during five decades: documentation of the content and quality of the register.
Eur J Epidemiol
; 38(1): 109-120, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36595114
14.
Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study.
Ann Rheum Dis
; 81(5): 729-736, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35027398
15.
Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?
Ann Rheum Dis
; 81(3): 433-439, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34810197
16.
EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology.
Ann Rheum Dis
; 81(6): 780-785, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35058229
17.
Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.
Rheumatology (Oxford)
; 61(5): 1810-1818, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34324640
18.
Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden.
Rheumatology (Oxford)
; 61(9): 3596-3605, 2022 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34919663
19.
Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data.
Rheumatology (Oxford)
; 61(10): 3952-3962, 2022 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35134119
20.
Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration.
Rheumatology (Oxford)
; 61(11): 4286-4296, 2022 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35139178